Not Yet RecruitingNot Applicable

Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation

South Korea500 participantsStarted 2026-05

Plain-language summary

This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators. Participants are randomized 1:1 into either an early screening or usual care group. * Early screening group : AI- ECG and/or CT-ECV analysis + AF treatment * Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 19 or older who have provided voluntary written informed consent. * Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms/signs. * Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis. Exclusion Criteria: * Patients previously diagnosed with cardiac amyloidosis (AL or ATTR). * Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year. * Patients deemed inappropriate for participation by the investigator.

What they're measuring

Cardiac amyloidosis(CA) detection rate

Timeframe: From enrollment to the 2 year follow-up

Trial details

NCT IDNCT07567508

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-12-31

Contact for this trial

Ju Youn Kim, Ph.D

82+ 10-5482-7307 kzzoo921@gmail.com

View on ClinicalTrials.gov More Atrial Fibrillation (AF) trials